VVM
SKYE icon

Versant Venture Management’s Skye Bioscience SKYE Stock Holding History

Versant Venture Management’s Portfolio SKYE Stock Details SKYE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.23M Hold
2,007,704
– – 0.87% 7
2025
Q4 		$1.51M Hold
2,007,704
– – 1% 6
2025
Q3 		$7.89M Hold
2,007,704
– – 3.71% 5
2025
Q2 		$8.39M Hold
2,007,704
– – 10.22% 4
2025
Q1 		$3.19M Hold
2,007,704
– – 5.3% 4
2024
Q4 		$5.68M Hold
2,007,704
– – 6.55% 4
2024
Q3 		$7.85M Hold
2,007,704
– – 12.35% 4
2024
Q2 		$16.1M Buy
+2,007,704
New +$23.8M 20.81% 3

Other funds holding SKYE

5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Versant Venture Management's SKYE Position: Q1 2026 in Review

Versant Venture Management held its Skye Bioscience (SKYE) position steady in Q1 2026 at 2,007,704 shares worth $1.23M. The position accounts for 0.87% of the portfolio, ranked #7.

Versant Venture Management first reported a position in SKYE in Q2 2024 and has held it in 8 quarters since. The position peaked at $16.1M in Q2 2024. 39 funds tracked by Wall St. Rank hold SKYE as of Q1 2026.

  • Versant Venture Management held 2,007,704 shares of Skye Bioscience worth $1.23M as of Q1 2026.
  • Versant Venture Management left its Skye Bioscience share count unchanged in Q1 2026.
  • Skye Bioscience made up 0.87% of Versant Venture Management's portfolio in Q1 2026, its #7 holding.
  • Versant Venture Management first reported a position in Skye Bioscience in Q2 2024 and has held it in 8 quarters since.
  • Versant Venture Management's Skye Bioscience position peaked at $16.1M in Q2 2024.
  • 39 funds tracked by Wall St. Rank held Skye Bioscience as of Q1 2026.

Based on Versant Venture Management's 13F filing for Q1 2026, filed 5 May 2026.